Targeting Aβ and phosphorylated tau ameliorate and/or reverse memory and synaptic deficits in 3xTg-AD mice7, although it is still unclear whether targeting tau independently of Aβ may have therapeutic benefits on cognition and/or emotional symptoms at late AD stages. The gene discussed is MAPT; the disease is Alzheimer disease.